Researchers describe a metabolic "settling in" where their body seems to find a new equilibrium
It also captures exposure to supplements, fortified products, energy products, and injections with their timing, the symptoms and examination findings, the comorbidities, and the related laboratory results reviewed, followed by the plan, its rationale, and clear safety-net instructions
However, those who continue the mindful eating patterns, regular exercise, and nutrition habits they developed during treatment can maintain much of their progress
Because of their precision, peptides are reported to cause very few, if any, side effects
Most studies were double-blind, with the exception of PIONEER 2 and 10 (which were open-label studies), and PIONEER 9 was a combination of double-blind for semaglutide tablets and placebo, and open-label liraglutide